NextGen Acquires Patent Application for Breast Cancer Stem Cell Treatment
April 08 2008 - 6:30AM
Marketwired
LONDON, UNITED KINGDOM (PINK SHEETS: NXGB), a biotechnology
company that develops novel therapeutic proteins that disrupt the
advance of life-threatening cancers, today announced it has
acquired use, commercialisation and ownership rights of a patent
application for the treatment of cancer from Oxon Life Science
Inc.
The patent application describes an improved method of
identifying and purifying undifferentiated stem cells from solid
breast carcinomas that are normally resistant to conventional
therapies. The cancer stem cell is typically represented as a
distinct population of cells within a tumour which may remain even
if the rest of the tumour is destroyed, through chemotherapy, or
other anti-cancer therapies. This may lead to the subsequent
re-occurrence of the cancer at a later date, a relapse, which is
devastating for the patient. These cancer stem cells, precursors of
cancer, possess certain characteristics, which can be targeted to
allow identification.
NextGen CEO, Konstantinos Kardiasmenos, stated, "Based on
evidence that cancers such as breast cancer and prostate cancer
proliferate primarily from cancer stem cells, this technology will
be vital for both early diagnosis and identifying targets for a new
generation of targeted therapeutic strategies."
"Acquiring the patent application for this innovative
biotechnology is an exciting early step in its progress toward
commercialisation," he said.
About NextGen Bioscience Inc.
NextGen is positioning itself as the world's leading bioscience
company in the development and commercial licensure of novel
therapeutic proteins that disrupt the advance of life-threatening
cancers. The company leverages cutting-edge research collaborations
to achieve breakthroughs in anti-cancer treatments, and then
licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies.
At present, NextGen is rapidly building its portfolio of
proprietary biotechnology. NextGen's target market --cancer
treatments-- is the largest disease market, exploding at a 20%
growth rate each year. NextGen's treatment niche is based on recent
discoveries that indicate that most tumors may be derived from a
single cancer-initiating cell population which has stem cell
properties (a cancer stem cell). NextGen has chosen to concentrate
on identification of certain cell-specific characteristics, making
it possible to identify precursor cells of tumors, and then conduct
a more extensive 'fingerprinting' profile that will enable the
development of cell-specific anti-cancer treatments. This will
result in a 'tailor made' cancer treatment strategy that is
superior to existing therapies in its ability to eradicate
malignant cells whilst leaving healthy tissue intact.
Statements about NextGen's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. NextGen's actual results could differ
materially from expected results. NextGen undertakes no obligation
to update forward-looking statements to reflect subsequently
occurring events or circumstances.
For more information about NextGen Bioscience Inc., or to
schedule an interview with Mr. Kardiasmenos, please contact
Investor Relations at +44 20 7247 8186 or
investorrelations@nextgenbioscience.com.
Contacts: NextGen Bioscience, Inc. Konstantinos Kardiasmenos +44
(0) 20 7247 8186 +44 (0) 20 7377 9454 (FAX) Email:
investorrelations@nextgenbioscience.com Website:
www.nextgenbioscience.com
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Mar 2024 to Apr 2024
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Apr 2023 to Apr 2024